Changing the way that inflammatory diseases are treated
Koutif Therapeutics is advancing discoveries from researchers at the University of Pittsburgh. Our academic founders are developing an inhibitor of E3 ligase Fbxo3, which is implicated in the pathogenesis of inflammatory conditions such as inflammatory bowel disease (including ulcerative colitis and Crohn’s Disease), bronchiolitis obliterans syndrome, chronic obstructive pulmonary disease, acute lung injury, and rheumatoid arthritis. The lead compound has successfully completed IND-enabling studies. Koutif has completed all IND-Enabling studies for its lead compound and has filed for the IND in January 2019. The company is preparing to enter into human clinical trial testing later this year.